Spotlight PA is an unbiased, nonpartisan newsroom powered by The Philadelphia Inquirer in partnership with PennLive/The Patriot-Information, TribLIVE/Pittsburgh Tribune-Evaluate, and WITF Public Media. Sign up for our free newsletters.
HARRISBURG — Some Pennsylvania hashish corporations are utilizing incomplete or deceptive claims to advertise marijuana as a therapy for opioid habit, doubtlessly placing sufferers’ lives at higher threat, a Highlight PA investigation has discovered.
In a first-of-its-kind evaluate, Highlight PA examined greater than 60 web sites providing providers in Pennsylvania and consulted quite a few well being coverage consultants concerning the validity of the claims. In some situations the place medical analysis was cited on an internet site or by an organization official, the information group straight contacted research authors.
The investigation discovered a variety of deceptive ways: cherry-picking and misrepresenting components of research, making broad claims with out citing any particular analysis, and offering incomplete details about what it takes to qualify for the state’s medical marijuana program.
About half the web sites promoted hashish dispensaries, whereas the opposite half had been for physicians or corporations that assist certify sufferers.
Probably the most alarming examples, in accordance with a number of of the consultants, had been on-line statements made by two corporations that assist sufferers grow to be licensed to purchase medical marijuana at state dispensaries.
With out citing particular proof, webpages for Releaf Specialists and Compassionate Certification Facilities used similar language to say analysis suggests medical marijuana could be a “viable substitute” for buprenorphine, certainly one of three medicine accepted by the federal authorities to deal with opioid use dysfunction.
A number of well being coverage consultants, hashish researchers, and medical suppliers advised Highlight PA the declare was inaccurate, deceptive, or probably harmful.
Officers with each corporations defended the language in response to questions from Highlight PA. However analysis supplied by every firm didn’t substantiate their claims as they advised, and among the authors of these journal articles strongly pushed again on the characterization of their work.
New York habit psychiatrist Adam Bisaga, an creator of one of many scientific articles cited, warned of the chance of utilizing marijuana as an alternative of one of many federally accepted opioid use dysfunction medicine, saying in an e-mail that “advocating substituting hashish for buprenorphine, methadone, or naltrexone just isn’t based mostly on any analysis and it could be harmful.”
The state of affairs exemplifies the confusion and combined messages sufferers obtain in Pennsylvania, a state with one of many highest deadly drug overdose charges within the nation and one of many few to particularly endorse hashish as a therapy choice for individuals with opioid use dysfunction.
Regardless of Pennsylvania’s outlier standing and the excessive stakes for individuals searching for therapy, state regulators do little to make sure hashish dispensaries make correct medical claims on their very own web sites, hundreds of pages of data obtained by means of Proper-to-Know requests present.
And whereas the state’s 2016 medical marijuana regulation requires the Division of Well being to limit the promoting and advertising and marketing of hashish, it doesn’t particularly point out the certification corporations that always play a vital function in connecting sufferers with physicians. A division spokesperson mentioned the company doesn’t “have any regulatory authority” over these corporations.
Chelsea L. Shover, an epidemiologist and assistant professor-in-residence on the David Geffen College of Drugs at UCLA, mentioned selling hashish as an alternative choice to buprenorphine as an opioid use dysfunction therapy is “actually harmful.”
“That’s full nonsense. If it had been as much as me, you wouldn’t be allowed to make claims like that,” mentioned Shover, who has studied state hashish insurance policies and unsupported medical claims made by dispensaries, after reviewing Highlight PA’s findings. “That’s type of the worst-case situation of this promoting.”
Shover was removed from the one knowledgeable alarmed to see hashish corporations in Pennsylvania making this declare. Individuals with opioid use dysfunction are about 50% much less prone to die when they’re handled long-term with buprenorphine or methadone, a significant nationwide consensus research present in 2019. No such proof exists for hashish.
“That’s horrible,” mentioned Erin Zerbo, an habit psychiatrist in New Jersey and an affiliate professor at Rutgers New Jersey Medical College, as she reviewed Highlight PA’s findings. “‘A viable substitute?’ No, that’s unhealthy.”
Among the many different findings of Highlight PA’s investigation:
Seven web sites cited a 2014 research that discovered medical marijuana legal guidelines had been related to decrease charges of deadly opioid overdoses. However they ignored a later research that confirmed the pattern didn’t maintain up over time and, the truth is, reversed. (One dispensary web site eliminated such a reference after Highlight PA contacted it in December.)
Seven promoted the advantages of the hashish compound CBD for opioid habit therapy, together with to assist with withdrawal or cut back cravings. However a number of consultants advised Highlight PA that a minimum of among the messages went past what analysis helps.
The Wolf administration says opioid use dysfunction ought to solely be a qualifying situation for medical marijuana in sure circumstances, similar to when typical therapies are ineffective, however a minimum of 13 web sites didn’t embody these caveats after they described what it takes for habit sufferers to qualify for hashish.
“The findings reveal a considerably misleading technique — whether or not intentional or not — adopted by many dispensaries and hashish certification web sites the place very particular and restricted scientific analysis is usually cited to help very broad statements about hashish’ advantages,” Stephanie Lake, a postdoctoral fellow on the UCLA Hashish Analysis Initiative, mentioned in an e-mail. “The results of this technique is an oversimplified and scientifically inaccurate message about hashish.”
Keith Humphreys, an habit researcher and professor at Stanford College College of Drugs, mentioned medical hashish corporations needs to be held to a better customary than nonmedical companies.
“Virtually all the pieces in right here is, if not a lie, pushing the border of fact,” Humphreys mentioned after reviewing Highlight PA’s findings and examples.
When Pennsylvania lawmakers legalized medical hashish in 2016, they put safeguards in place for the messages sufferers obtain. However these have important limits.
The Pennsylvania Division of Well being has the authority to approve or reject promoting, promotional, and advertising and marketing supplies from hashish dispensaries, growers, and processors.
However the division hardly ever makes use of its energy to make sure these corporations make correct medical claims on their web sites and social media, in accordance with data obtained by means of the state’s Proper-to-Know regulation relationship again to the beginning of this system.
When the company did take enforcement motion, the difficulty usually was whether or not medical marijuana dispensaries didn’t observe the required approval course of for submitting promoting and advertising and marketing supplies to the Division of Well being, or whether or not they made references to leisure use.
Brendan Saloner, an affiliate professor at Johns Hopkins Bloomberg College of Public Well being, is an creator of a 2014 research that discovered medical marijuana legal guidelines had been related to decrease charges of deadly opioid overdoses. That analysis has been cited by dispensaries and certification corporations in deceptive methods.
Saloner mentioned Highlight PA’s findings had been “positively in step with the necessity for extra oversight.”
“There’s a necessity to speak with shoppers in a constant method that when dispensaries or different marijuana retailers are making claims that these claims needs to be vetted for accuracy,” he mentioned.
Well being division spokesperson Maggi Barton mentioned the company “continues to work with medical marijuana dispensaries to make sure they’re offering top quality providers to Pennsylvanians for all accepted medical circumstances.” Barton additionally advised, in some circumstances, the division didn’t have sufficient employees to maintain up with the quantity of promotional and advertising and marketing supplies.
Barton mentioned the division doesn’t have enforcement energy over hashish certification corporations like Releaf Specialists and Compassionate Certification Facilities, which join individuals to medical doctors who make consequential therapy selections.
Releaf Specialists described itself on-line as “an business chief,” whereas Compassionate Certification Facilities’ web site promoted “PA’s Most Trusted Medical Marijuana Certification Suppliers.”
In sections of their web sites targeted on opioid habit, every displayed similar statements: “Analysis means that medical marijuana could be a viable substitute for opioids similar to buprenorphine and different prescribed drugs.” Neither webpage included a hyperlink to mentioned analysis.
Releaf Specialists proprietor Bob Scherer, who’s not a doctor, advised the web site language was supplied by a third-party contractor that he declined to call. He defended the assertion, saying it’s “broad and generalized sufficient that it permits sufferers to find and do extra analysis about how hashish may help them” with opioid habit.
“I’m simply saying that, based mostly off of the state tips, and if sufferers haven’t had constructive outcomes with conventional therapies, then hashish may very well be a viable means for them, and so they have the choice within the state of Pennsylvania to strive it,” he mentioned.
Scherer later shared two medical science journal articles with Highlight PA to help the declare.
Considered one of them was an article co-authored by Bisaga, the New York habit psychiatrist who advised Highlight PA he was involved about the potential of individuals with opioid use dysfunction utilizing hashish as an alternative choice to federally accepted remedy.
The opposite journal article Scherer shared was a evaluate of present analysis, and it included context and notes of warning that Releaf Specialists’ webpage didn’t. In a bit titled “Shortcomings of Hashish in Treatment-Assisted Remedy,” the authors wrote there was conflicting proof for the effectiveness of hashish for “therapy for opioid misuse.”
Beth Wiese, a neuroscience doctoral candidate on the College of Arizona and an creator of the article, mentioned she helps having opioid use dysfunction as a qualifying situation for hashish however she nonetheless sounded a observe of warning.
“I don’t know that we’re there to name it a substitute but,” Wiese mentioned. “Some people could discover that it really works higher for them instead. However different individuals, it could not. I simply don’t assume we’re there to know precisely.”
Compassionate Certification Facilities leaders additionally defended the language and shared two medical science journal articles in protection, neither of which claimed medical marijuana could be a viable substitute for buprenorphine.
Chief Govt Officer Melonie Kotchey — who has an MBA in health-care administration and medical billing and coding, in accordance with the corporate’s web site — additionally referred Highlight PA to a report on the corporate’s web site. Kotchey didn’t specify which report, however her description matched one dated December 2019 that was based mostly on a affected person survey the corporate helped develop.
That report didn’t examine outcomes for sufferers who use hashish as an alternative of buprenorphine, which isn’t talked about in any respect. It additionally lumped collectively a number of circumstances, saying 99.62% of sufferers surveyed “had been in a position to cut back ache, higher sleep, much less anxiousness, much less seizures, urge for food enhance, much less vomiting, nausea, habit withdrawal signs, lower with muscle spasms, improved power and fewer seizures.”
Bradford Buege, a doctor who the corporate web site describes as board-certified in household apply and emergency medication, didn’t cite any research in an e-mail to Highlight PA. “My [patients’] enter is and all the time shall be valued extra above all else,” Buege wrote. “[D]on’t contact me once more w your pharmaceutical bs.”
Jennifer Hawks, the corporate’s chief medical director, took the argument in favor of hashish over buprenorphine additional than the webpage, saying in an e-mail that hashish and the hashish compound CBD “are a lot much less invasive and far safer than buprenorphine by far.” A 2019 report from the Nationwide Academies of Sciences, Engineering, and Drugs mentioned buprenorphine and different federally accepted medicines for opioid use dysfunction “are protected and extremely efficient.”
Hawks is a licensed naturopathic physician in Arizona, a state the place these practitioners can certify sufferers for hashish. That’s not the case in Pennsylvania, in accordance with the Wolf administration.
Hawks cited two medical science journal articles, however neither examined habit therapy outcomes for individuals who used medical marijuana versus buprenorphine.
Matisyahu Shulman, an habit psychiatrist in New York and an creator of one of many articles, advised Highlight PA that the purpose of a bit Hawks cited is that folks ought to use buprenorphine as a long-term therapy, not for only a week or two weeks. The article, an outline of analysis on buprenorphine, didn’t point out hashish or CBD.
Shulman advised Highlight PA “buprenorphine saves lives,” and he mentioned utilizing something aside from a federally accepted remedy for opioid use dysfunction is “fairly harmful.”
Neuroscientist Yasmin Hurd, a number one CBD researcher and an creator of the second article Hawks cited, referred to as Compassionate Certification Facilities’ on-line statements about hashish and opioid use dysfunction “blatantly incorrect” and “past deceptive.”
“They’re giving false hope,” Hurd advised Highlight PA.
Hurd, director of the Dependancy Institute on the Icahn College of Drugs at Mount Sinai, hopes the hashish compound CBD will in the future grow to be a federally accepted remedy for opioid use dysfunction.
She and her colleagues have discovered CBD can cut back cue-induced craving and anxiousness for individuals who have a historical past of heroin use, however she mentioned these had been smaller research that lay the groundwork for extra analysis. A 2019 research by Hurd and fellow researchers, as an illustration, examined 42 sufferers over 10 days, and her group mentioned long-duration therapy research had been wanted.
And he or she advised Highlight PA it’s essential to tell apart between CBD, which is one compound of hashish, and medical marijuana, which incorporates many compounds that may have completely different results. They aren’t interchangeable, Hurd mentioned.
“We should always maintain individuals accountable, particularly immediately, to be very clear about what’s it that they’re selling and actually substantiate that,” Hurd mentioned.
When Pennsylvania added opioid use dysfunction as a qualifying situation for medical marijuana in 2018, the Wolf administration mentioned it was the primary state to take such an motion.
An April report from that yr written by the state’s Medical Marijuana Advisory Board cleared the best way for the change, however didn’t cite any particular analysis to help it. As an alternative, the report mentioned hashish had “been reported by sufferers to ease the signs and means of opioid withdrawal. It has been utilized by sufferers as an ‘exit drug’ to get off of heroin and different opiates.”
A number of well being coverage consultants advised Highlight PA that some individuals might need success utilizing hashish as an alternative choice to different medicine. However they mentioned there are limits to counting on particular person tales and anecdotes for creating broad coverage or tips on find out how to deal with sufferers — particularly when there may be good proof behind different therapies.
“The way in which my area works is you’ll be able to’t go from, ‘Nicely, one individual can do it’ to ‘This needs to be a therapy for 1,000 individuals,’’ mentioned M-J Milloy, an epidemiologist and analysis scientist on the British Columbia Centre on Substance Use in Canada. “There’s lots of optimism round hashish being an alternative choice to these types of issues. However we’re not there but by way of what has been confirmed by means of managed trials and different high-quality scientific research.”
The state’s well being secretary on the time, doctor Rachel Levine, additionally didn’t cite any particular analysis when she formally added opioid use dysfunction as a qualifying situation. Levine mentioned opioid use dysfunction ought to solely be a qualifying situation in sure circumstances: when typical therapies are contraindicated or ineffective, or if hashish is used alongside one other main remedy.
“It’s essential to notice that medical marijuana just isn’t an alternative choice to confirmed therapies for opioid-use dysfunction,” Levine, who now serves in President Joe Biden’s administration, mentioned in a information launch on the time.
Pennsylvania’s laws enable any of its licensed hashish medical doctors to certify for opioid use dysfunction. At a Medical Marijuana Advisory Board assembly in Could 2019, pediatric neurologist William Trescher raised considerations concerning the apply, saying he didn’t know what number of of these physicians had been “true consultants” in habit.
“They’ll say the individual has it,” Trescher, a board member on the time, mentioned in accordance with a gathering transcript. “However I don’t know in the event that they’re going to know find out how to handle it.”
Neighboring New York has created a better bar. As a way to approve hashish for opioid use dysfunction there, practitioners should even have a federal waiver to dispense and prescribe buprenorphine.
The requirement helps guarantee these practitioners have some expertise treating sufferers with a substance use dysfunction, Freeman Klopott, a spokesperson for the state’s Workplace of Hashish Administration, advised Highlight PA.
Deepika Slawek, a New York doctor, co-authored new medical tips for practitioners in that state’s medical hashish program. The authors mentioned if there’s a function for medical hashish to handle opioid use dysfunction, “it is going to be to enhance relatively than substitute” buprenorphine or methadone.
“[E]vidence to help taking medical hashish to deal with opioid use dysfunction (OUD) is scant,” the authors wrote. “Randomized managed medical trials are wanted to grasp the connection between medical hashish use and opioid-related outcomes.”
By limiting who can approve hashish to deal with habit, Slawek mentioned she hopes these suppliers are “possible providing buprenorphine in the beginning.”
However the requirement highlights a major problem: Slawek says there are already too many federal restrictions on which practitioners can prescribe buprenorphine. That creates significant barriers for patients.
The American Society of Dependancy Drugs tells practitioners to not suggest hashish for the therapy of opioid use dysfunction. Zerbo, the habit psychiatrist in New Jersey, has a nuanced view.
She believes hashish may help some sufferers with opioid use dysfunction in the event that they use it along with a main therapy. However she mentioned suppliers “should be very cautious to clarify to everybody that it’s not” a alternative for the federally accepted medicine.
“If we don’t put individuals on remedy, the relapse charge is so excessive, and other people lose their tolerance,” Zerbo mentioned. “They usually’re so more likely to die.”
WHILE YOU’RE HERE… When you discovered one thing from this story, pay it ahead and grow to be a member of Spotlight PA so another person can sooner or later at spotlightpa.org/donate. Highlight PA is funded by foundations and readers like you who’re dedicated to accountability journalism that will get outcomes.